Which Do You Lose More Weight On: Ozempic or Wegovy?

Last reviewed: June 29, 2026

Last updated: June 29, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Ozempic and Wegovy are both semaglutide injections, yet they represent two different treatment pathways with measurably different outcomes for weight loss. While Ozempic targets blood sugar control in type 2 diabetes patients, Wegovy was specifically developed and dosed for weight management in people without diabetes. Clinical trials show that the higher, more frequent doses used in Wegovy protocols produce greater weight reduction than typical Ozempic dosing.

The Core Difference: Same Drug, Different Dosing Strategies

Ozempic and Wegovy both contain semaglutide as their active compound, but the dosing approach creates a significant gap in weight loss outcomes. Ozempic begins at 0.25 mg weekly and typically tops out at 1 mg weekly for diabetes management, focusing on glucose control rather than maximal weight reduction. Wegovy follows a more aggressive titration protocol, climbing to 2.4 mg weekly—a dose never reached in Ozempic treatment plans. This twofold difference in target dose directly correlates with stronger appetite suppression and metabolic effects.

The reason for this divergence lies in regulatory approval and clinical intent. The FDA approved Ozempic primarily to lower blood sugar and reduce cardiovascular risk in diabetic populations, where lower doses achieve those goals effectively. Wegovy received separate FDA approval with a weight-loss indication, allowing prescribers to pursue higher maintenance doses that produce greater fat loss without additional diabetes-related benefits justifying the higher dose in a non-diabetic person.

Weight Loss Results: Clinical Evidence From Trials

Wegovy's pivotal trial, STEP 1, demonstrated that participants on the 2.4 mg weekly dose lost an average of 15% of their body weight over 68 weeks, with many individuals achieving 20% reduction or more. By contrast, Ozempic trials in non-diabetic weight-loss studies showed average reductions closer to 4–6% when used off-label, since the approved diabetes dosing was never optimized for weight management alone. This 10-percentage-point difference translates to approximately 25–35 pounds of additional weight loss for a 250-pound person choosing Wegovy-level dosing versus standard Ozempic protocols.

The disparity widens when comparing head-to-head data on appetite suppression markers and metabolic rate changes. Higher semaglutide concentrations in the Wegovy dose range produce more robust GLP-1 receptor activation in satiety centers of the brain, leading to sustained feelings of fullness and reduced meal portions. Patients on Wegovy protocols report greater difficulty finishing normal-sized meals and markedly decreased cravings for sugary and fatty foods compared to those on lower Ozempic doses.

Semaglutide Dosing and Personalization: Finding Your Optimal Level

Not every person requires 2.4 mg weekly to achieve meaningful weight loss, and not everyone tolerates higher doses without side effects. Some individuals respond strongly to 1 mg or 1.7 mg, experiencing substantial appetite reduction and steady fat loss while maintaining better gastrointestinal tolerance. PlexusDx recognizes this variability by offering compounded semaglutide injections that allow flexible dosing tailored to individual metabolism and response, at $189/mo month-to-month, or from $149/mo on the 6-month plan regardless of the final dose your provider selects. Your dose may need to go up. Your price won't.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR (rs1800437) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Cost, Access, and Choosing Between Ozempic and Compounded Semaglutide

Ozempic typically costs $900–$1,400 per month through most insurance plans, or $1,500+ without coverage, since it is a branded pharmaceutical. Wegovy carries similar pricing, often $1,200–$1,600 monthly out-of-pocket, making both inaccessible for uninsured or underinsured patients. PlexusDx compounded semaglutide injection achieves comparable clinical outcomes at a fraction of that cost, at $189/mo month-to-month, or from $149/mo on the 6-month plan through licensed 503A compounding pharmacies serving all 50 states. No insurance is required, no membership fee applies, and HSA and FSA funds are accepted.

Choosing between branded Ozempic, branded Wegovy, and compounded semaglutide ultimately depends on your insurance coverage, dosing needs, and preference for pharmaceutical versus compounded formulations. All three deliver the same active ingredient; the difference is in price, availability, and whether your healthcare provider can adjust your dose freely without tier-based insurance restrictions. PlexusDx patients benefit from direct prescriber collaboration and the flexibility to reach their therapeutically optimal dose without financial penalty.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Will I lose more weight on Wegovy than Ozempic?

On average, yes—Wegovy's higher target dose (2.4 mg weekly) produces approximately 10–15% greater weight loss than standard Ozempic dosing (1 mg weekly) in clinical trials. However, individual response varies significantly; some people achieve excellent results on lower doses. PlexusDx compounded semaglutide allows your provider to find your optimal dose and increase it gradually without cost increases.

Can I use Ozempic off-label for weight loss if I don't have diabetes?

Technically yes, but Ozempic's prescribing information and dosing schedule prioritize diabetes management, meaning providers may limit you to lower doses even for weight loss. Wegovy and compounded semaglutide protocols are designed specifically for weight management and allow escalation to 2.4 mg without restriction. Discuss your goals with your provider to determine the best approach for your situation.

How much does PlexusDx compounded semaglutide cost compared to branded options?

PlexusDx compounded semaglutide injection is $189/mo month-to-month (or $149/mo on the 6-month plan), regardless of your dose level, compared to $1,200–$1,600+ monthly for branded Wegovy or Ozempic. Your dose may need to go up. Your price won't. No insurance, membership fees, or prior authorizations required; HSA/FSA funds are eligible.

Are compounded semaglutide injections as safe and effective as branded versions?

Yes—PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies that follow strict pharmaceutical standards and quality controls. The active ingredient, manufacturing process, and clinical outcomes are equivalent to branded formulations. Like all semaglutide, gastrointestinal side effects (nausea, constipation) are common but typically mild and temporary.

How does the PlexusDx Precision Peptide Genetic Test help with semaglutide treatment?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR (rs1800437)) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Can My Dna Tell Me How Do You Lose Weight
• Can A Dna Test Tell Me How Do You Lose Weight
• Can You Get A Dna Test To See How Do You Lose Weight
• Ozempic For Losing Weight

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.